Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial.
OBJECTIVE
This study aimed to assess the cost effectiveness of ziprasidone versus haloperidol in sequential intramuscular (IM)/oral treatment of patients with exacerbation of schizophrenia in Spain.


METHODS
A cost-effectiveness analysis from the hospital perspective was performed. Length of stay, study medication and use of concomitant drugs were calculated using data from the ZIMO trial. The effectiveness of treatment was determined by the percentage of responders (reduction in baseline Brief Psychiatric Rating Scale [BPRS] negative symptoms subscale >or=30%). Economic assessment included estimation of mean (95% CI) total costs, cost per responder and the incremental cost-effectiveness ratio (ICER) per additional responder. The economic uncertainty level was controlled by resampling and calculation of cost-effectiveness acceptability curves.


RESULTS
A total of 325 patients (ziprasidone n = 255, haloperidol n = 70) were included in this economic subanalysis. Ziprasidone showed a significantly higher responder rate compared with haloperidol (71% vs 56%, respectively; p = 0.023). Mean total costs were euro3582 (95% CI 3226, 3937) for ziprasidone and euro2953 (95% CI 2471, 3436) for haloperidol (p = 0.039), mainly due to a higher ziprasidone acquisition cost. However, costs per responder were lower with ziprasidone (euro5045 [95% CI 4211, 6020]) than with haloperidol (euro5302 [95% CI 3666, 7791], with a cost per additional responder (ICER) for ziprasidone of euro4095 (95% CI -130, 22 231). The acceptability curve showed an ICER cut-off value of euro13 891 at the 95% cost-effectiveness probability level for >or=30% reduction in BPRS negative symptoms.


CONCLUSIONS
Compared with haloperidol, ziprasidone was significantly better at controlling psychotic negative symptoms in acute psychoses. The extra cost of ziprasidone was offset by a higher effectiveness rate, yielding a lower cost per responder. In light of the social benefit (less family burden and greater restoration of productivity), the incremental cost per additional responder with sequential IM/oral ziprasidone should be considered cost effective in patients with exacerbation of schizophrenia in Spain.
Cañas
Fernando
F
Department of Psychiatry, Hospital Rodríguez Lafora, Madrid, Spain.
Pérez-Solá
Víctor
V
Díaz
Silvia
S
Rejas
Javier
J
D000284:Administration, Oral; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000191:economics*; D010054:Brief Psychiatric Rating Scale; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage* / Q000191:economics*; D017721:Hospital Costs; D006801:Humans; D007273:Injections, Intramuscular; D007902:Length of Stay / Q000191:economics; D008297:Male; D010879:Piperazines / Q000008:administration & dosage* / Q000191:economics*; D011788:Quality of Life; D012107:Research Design; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics*; D013030:Spain; D013844:Thiazoles / Q000008:administration & dosage* / Q000191:economics*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone; D006220:Haloperidol
Gen Hosp Psychiatry. 2005 Mar-Apr;27(2):140-4
15763126
Lancet. 2004 Jun 19;363(9426):2063-72
15207959
N Engl J Med. 2003 Oct 30;349(18):1738-49
14585943
J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):257-64
11001606
Eur J Pharmacol. 2001 Aug 17;425(3):197-201
11513838
Acta Psychiatr Scand. 1997 Oct;96(4):265-73
9350955
Soc Psychiatry Psychiatr Epidemiol. 2004 Jul;39(7):507-13
15243687
Arch Gen Psychiatry. 1997 Jun;54(6):549-57
9193196
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003079
16235313
J Clin Psychiatry. 2001 Jan;62(1):12-8
11235922
J Ment Health Policy Econ. 2001 Mar 1;4(1):25-34
11967463
Arch Gen Psychiatry. 1991 Mar;48(3):239-46
1671741
Ann Clin Psychiatry. 2004 Jul-Sep;16(3):145-54
15517847
Am J Health Syst Pharm. 2002 Sep 1;59(17 Suppl 5):S4-11
12227084
J Clin Psychiatry. 2005 Sep;66(9):1122-9
16187769
J Psychiatry Neurosci. 1993 Jan;18(1):18-23
8461276
Schizophr Res. 1999 May 4;37(1):13-20
10227104
Can J Psychiatry. 1999 Jun;44(5):464-72
10389607
Lancet. 1999 Jul 10;354(9173):111-5
10408486
Acta Psychiatr Scand Suppl. 2006;(429):60-3
16445484
Eur Psychiatry. 2005 Aug;20(5-6):386-94
16171653
J Abnorm Psychol. 1998 May;107(2):355-9
9604565
J Clin Psychiatry. 2003;64 Suppl 19:13-8
14728085
Psychopharmacology (Berl). 1998 Nov;140(2):173-84
9860108
Soc Psychiatry Psychiatr Epidemiol. 1997 Feb;32(2):104-8
9050352
Schizophr Bull. 1994;20(3):557-66
7973471
Biol Psychiatry. 1997 Aug 15;42(4):233-46
9270900
Acta Psychiatr Scand. 1996 Aug;94(2):118-24
8883573
Online J Issues Nurs. 2004 Nov 29;10(1):7
15727542
Psychopharmacology (Berl). 2005 Apr;178(4):514-23
15650846
Acta Psychiatr Scand. 1999 Nov;100(5):359-66
10563453
CNS Drugs. 2002;16(4):219-28
11945106
J Clin Psychiatry. 2000 Dec;61(12):933-41
11206599